FDA has decided not to move forward with a 2016 proposal that would have required makers of many class II and III devices intended for use in patients' homes to submit labeling and package inserts in electronic form to the agency.
"FDA does not plan to finalize the 2016 proposal," the agency announces in the US Department of Health and Human Services Fall 2018 Unified Agenda of Federal Regulatory and Deregulatory Actions, posted online Oct. 17. The reversal comes after extensive pushback from device companies.
The electronic submissions would have formed the basis of an FDA-administered public database of home-use device labeling and instructions. It was intended as a resource for patients and caregivers to enhance device safety in the home environment. (Also see "Electronic Labeling Submissions Proposed For Home-Use Devices" - Medtech Insight, 18 Oct, 2016.)
But device-makers argued that the mandatory e-submissions would be unnecessarily onerous and cause more confusion that benefit for patients. Companies said in comments submitted in response to the 2016 proposed rule that the mandatory effort would be redundant to labeling information already provided on manufacturer websites. (Also see "FDA Home-Use e-Labeling Proposal Gets Serious Pushback From Medtech Firms" - Medtech Insight, 26 Jan, 2017.)
The Unified Agenda also signaled that FDA may soon finalize another rule that made industry nervous in the proposal phase.
The agency says that a 2014 proposed rule on "medical device classification procedures" is on tap to be finalized in November. Ostensibly, the rule is intended to implement provisions of the 2012 FDA Safety and Innovation Act that require FDA to reclassify devices using administrative orders rather than formal, and more time-consuming, regulations.
But the 2014 proposal also included more prescriptive language to explain what types of devices should be designated to the most significantly regulated class III category and are not suitable for down-classification. (Also see "What Makes A Device Class III? FDA Proposes New Language To Clarify" - Medtech Insight, 24 Mar, 2014.) Device industry groups said the proposed language, if finalized, would lead to more devices requiring PMAs to enter the US market. (Also see "More PMAs Would Result From FDA’s Classification Proposed Reg, AdvaMed Warns" - Medtech Insight, 23 Sep, 2014.)
FDA could finalize the rule with similar wording to the proposal or it could make substantive changes in response to the industry comments.
HHS' fall agenda includes other FDA medical device regulations as well, including several that have been on the agency's list for some time and others that are newer additions. Here is a sampling of noteworthy proposed and final rules to look out for, including planned release dates:
De novo rule this month? A proposed rule to map out the process forde novo classifications could see the light of day as early this month, following an FDA guidance issued in 2017 detailing updates to the program for low- to- moderate-risk devices with no predicate. (Also see "De Novo Policies Clarified In Final Guidance" - Medtech Insight, 1 Nov, 2017.) (Proposed rule; October 2018)
No more quarterly PMA and HDE listings: FDA plans to propose amended regulations that would end its quarterly listings of PMA and humanitarian device exemption approvals to improve efficiency and eliminate duplication. (Proposed rule; June 2019)
Amending and repealing device software regulations: A proposed rule could be issued as early as November to implement the 21st Century Cures provisions to exclude certain medical software functions from the definition of a medical device. (Also see "US FDA Asks For Public Input On Software It Can't Regulate" - Medtech Insight, 29 May, 2018.) (Proposed rule; November 2018)
Supervisory review final rule: The agenda suggests FDA plans to finalize its January 2018 proposed rule explaining the supervisory review and appeals process for devices by June 2019. (Also see "Appealing An FDA Device Decision? Proposed Rule Clarifies Framework" - Medtech Insight, 18 Jan, 2018.) (Final rule; June 2019)
Harmonizing QSR and ISO 13485: FDA's previously announced plan to harmonize its Quality System Regulation with the global ISO 13485 quality standard is slated to come out in proposed rule form in September 2019, according to the latest agenda. (Also see "QSR Author Kim Trautman Predicts What A Mash-Up Of FDA's Quality System Regulation And ISO 13485 Might Look Like" - Medtech Insight, 15 Aug, 2018.) (Proposed rule; September 2019)
Anthrax Dx classification: FDA's plan to designate IVDs for detection ofBacillus species as class II devices is on the road to possible finalization next March, according to the agenda. This would be about eight years since the agency originally proposed classification for the tests intended to aid in the diagnosis of anthrax and related diseases. (Also see "Regulatory Briefs: What's New From FDA" - Medtech Insight, 23 Nov, 2015.) (Final rule; March 2019).
From the editors of The Gray Sheet
Medtech Insight: 世界の医療機器・医療技術の最新情報
By Shawn Schmitt 01 Mar 2021
It’s yet another internal deadline missed by the US agency in publishing a draft of its overhauled Quality System Regulation...
Medtech Insight: 世界の医療機器・医療技術の最新情報
26 Feb 2021
Many elements need to be considered when notified bodies are deciding whether to undertake virtual audits in the context of...
Medtech Insight: 世界の医療機器・医療技術の最新情報
26 Feb 2021
Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.
製品説明＆デモお申込
専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。
＊一部のサービスでは無料トライアルをご利用になれません。
お問い合わせ先
新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問合せの際は下記メールアドレスまたは各営業スタッフまでご連絡下さいますようご協力をお願い申し上げます。
インフォーマインテリジェンス合同会社
ファーマインテリジェンス
inquiry.jp@informa.com
＊Omdia（ICT産業の情報）に関するお問い合わせはこちら
Contact_OmdiaJapan@omdia.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
Meddevicetracker(メッドデバイストラッカー)は、医療機器の開発状況について適応疾患や医療機器のタイプから検索できるツールです。1,000社以上の会社による5,000を超える製品群、2,000件以上の医療機器の臨床試験など比類ない規模で医療機器市場を網羅しています。
In Vivo(インビボ)は、医療用医薬品の企業全般、バイオ医薬品企業、医療機器・診断機器メーカーの経営層・トップマネジメントを対象としたニュース配信サービスです。35年以上の経験を有するベテランの専門記者とアナリストが様々な観点から今日の医薬品産業を分析し、経営層のハイレベルかつグローバルな情報ニーズに応えるニュースや読み応えのある記事を提供しています。
Pink Sheet(ピンクシート)では、医療用医薬品の承認審査を担当する世界中の規制当局の動きに関するニュースを配信しています。グローバルに拠点を置く専門記者とアナリストが、医療用医薬品の製造・販売許可を得るための申請から、承認を得るまでの進捗をカバーしています。世界の薬事規制は常に変化しており、医薬品メーカーのコンプライアンスに大きな影響を及ぼします。Pink Sheetのニュースなら各市場の医療政策や薬事規制の動向をカバーしているので、安全な臨床試験の計画と実施なども強力にサポートすることができます。
